Providers/Grant Support
Provided by The National Lipid Association
This program is supported by an independent educational grant from Chiesi.
Credits Available
- Physicians — maximum of 1.00 AMA PRA Category 1 Credit™
- Nurses — 1.0 Nursing Contact Hour
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed for dermatologists seeking to enhance their diagnostic skills in identification of the rare disease lipodystrophy.
Program Overview
Diagnosis of lipodystrophy is based on detailed medical history and a thorough physical examination to evaluate body fat loss. One of the remaining places where a complete physical examination occurs is the dermatologist’s office. By providing education on the physical signs of lipodystrophy, we can empower dermatologists to serve as an additional resource in identifying potential cases and helping to shorten the diagnostic journey for patients. This program will feature image-rich content to educate clinicians on the physical manifestations of lipodystrophy.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Recognize the key physical manifestations of lipodystrophy in diverse patient presentations.
- Apply appropriate screening techniques to identify potential cases of lipodystrophy, leading to timely and accurate referral to a lipid specialist in clinical practice.
- Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
Faculty
Abhimanyu Garg, MD
Professor of Internal Medicine
Chief, Section of Nutrition and Metabolic Disease
Division of Endocrinology
UT Southwestern Medical Center
Dallas, TX
Vinaya Simha, MD
Associate Professor, Division of Endocrinology
Mayo Clinic
Rochester, MN
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physician Credit Designation
The National Lipid Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Physician Assistant Credit Designation
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Nurse Credit Designation
The maximum number of hours awarded for this CE activity is 1.0 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Criteria for Success
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at https://www.freecme.com/. The deadline to claim credit is May 1, 2026.
Disclosure Information: Faculty, Planners & Reviewers
NLA staff have no relevant financial information to disclose.
Abhimanyu Garg, MD
Research: Chiesi USA, Regeneron, Intercept
Consultant: Chiesi USA, Regeneron
Board Member: Zvelt Therapeutics
Vinaya Simha, MD
Nothing to disclose.
NLA CME Committee Reviewers:
Scott Webster Shurmur, MD, FNLA, Vice-Chair-NLA Inter-Professional Continuing Education (ICPE) Committee
Consultant: Akcea
Disclosure of Unlabeled Use
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.